Available from: Bsn A (2023) Novo nordisk slss om patentet p Ozempic i Kina
Retatrutide (LY3437943) is a synthetic peptide analog designed as a triple hormone receptor agonist, targeting the glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon receptors.[1][2] It has a molecular weight of approximately 4,800 Da and is administered subcutaneously, with a half-life supporting once-weekly dosing.[3][4] Developed by Eli Lilly, it is currently in Phase 3 clinical trials for obesity and type 2 diabetes (T2D), showing potential for superior weight loss compared to existing therapies.[1][5] Key characteristics for compounding pharmacies include: Multi-Receptor Agonist : Combines actions of GIP, GLP-1, and glucagon for enhanced metabolic effects.[1][6] Lyophilized Form : Supplied as a stable powder for reconstitution, similar to other peptides.[7][8] Versatile Delivery : Primarily subcutaneous, but potential for customized formulations in research contexts.[7][9] This makes Retatrutide a candidate for specialized preparations in compounding settings, though regulatory restrictions apply
Actual rates of alopecia were low, ranging from roughly three to nine per 1,000 people per year, with between 11,000 and 15,000 people in each drug-class group
Decotiis generally opts for tirzepatide medications, which include Mounjaro and Zepbound
